Patent · US Active

HDAC4 nucleic acid administration to treat retinal disease

US8912153B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignee

President and Fellows of Harvard College · US

Inventors

Constance L. Cepko · Newton, US
Bo Chen · Martinez, US

Key dates

Filing date	Aug 13, 2009
Grant date	Dec 16, 2014
Priority date	—
Expiry date	May 18, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2799/025
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods for inhibiting retinal cell death by altering expression of one or more of HDAC4, HDAC5, HDAC6, HDAC7, and HIF1α in a retinal cell are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.